![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
Beijing, China & Seoul, South Korea:
YH003 together with PD-1 are being dosed in section II multi-regional scientific trials sponsored by Eucure Biopharma for pancreatic most cancers and melanoma in Australia, the US and China.
ISU ABXIS intends to deploy YH003 sequence to develop tri-specific antibody for the remedy of a number of tumor varieties.
Eucure Biopharma, a China-based clinical-stage biotechnology firm centered on the growth of antibody therapeutics, introduced immediately that it has entered into a collaborative settlement with ISU ABXIS Co., Ltd. (KOSDAQ: 086890), a Korea-based scientific stage firm creating immuno-oncology medicine.
Under the phrases of the settlement, ISU ABXIS will make the most of the sequence of YH003, Biocytogen’s humanized agonistic anti-CD40 antibody at present in section II scientific trials, to assemble a few teams of tri-specific antibodies and develop most cancers medicine for a number of indications using its know-how platform. Eucure Biopharma will obtain an upfront cost, milestone funds and royalties.
“Biocytogen utilized its unique evidence-based in vivo drug screening platform to obtain YH003, which has demonstrated a good preclinical safety and efficacy profile,” mentioned Dr. Rong Chen, Vice President of Biocytogen and CEO/CMO of Eucure Biopharma. “Further, YH003’s phase I clinical trials indicate good tolerability and safety profiles, as well as encouraging antitumor activities against several tumor types, including malignant melanoma and pancreatic cancer.”
“CD40 is a key co-stimulator in adaptive immune responses,” mentioned Yeob Hwang, CEO of ISU ABXIS. “We are glad for the opportunity to utilize Biocytogen/Eucure Biopharma’s anti-CD40 antibody (YH003), as it has outstanding efficacy and safety profiles, both preclinically and clinically. These favorable properties will undoubtedly accelerate our tri-specific antibody development against tumors.”
About YH003
YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single agent or together with anti-PD-1 monoclonal antibody medicine, YH003 demonstrated sturdy anti-tumor results in opposition to a number of tumor fashions in Biocytogen’s humanized CD40 mice, with out exhibiting hepatotoxicity or different toxicities. Pharmacodynamic research in mice signifies that YH003 considerably elevated the infiltration of anti-tumor T cells into tumors. The section I dose escalation research carried out in Australia indicated that YH003 mixed with PD-1 mAb (toripalimab) had glorious security and antitumor exercise in sufferers with superior strong tumors. Currently, YH003 is present process section II multi-regional scientific trials (MRCTs) for the remedy of sufferers with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC) and melanoma.
About EucureBiopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma focuses on antibody drug remedy for oncology and different indications. Relying on a sturdy scientific growth staff with intensive expertise, Eucure Biopharma develops revolutionary medicine to fulfill scientific wants for sufferers worldwide. The firm has established a product pipeline for greater than 10 targets, with two in section II MRCTs and two in section I scientific trials. For extra info, please go to https://www.eucure.com/en/index.
About Biocytogen
Biocytogen (HKEX: 02315) is a world biotechnology firm that drives the analysis and growth of novel antibody-based medicine with revolutionary applied sciences. Using its proprietary RenMab™ /RenLite® mice platforms for totally human monoclonal and bispecific antibody growth, Biocytogen has built-in its in vivo drug efficacy screening platforms and robust scientific growth experience to streamline the complete drug growth course of. Biocytogen is endeavor a large-scale venture to develop first-in-class and/or best-in-class antibody medicine for greater than 1000 targets, generally known as Project Integrum. This venture has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with firms round the world, together with a number of partnerships with multinational pharmaceutical firms (MNCs). Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For extra info, please go to http://en.biocytogen.com.cn.
About ISU ABXIS
ISU ABXIS is a biotechnology firm devoted to the growth of new and novel bio-therapeutics. Founded in 2001 with the aim of creating revolutionary antibody-based therapeutics to deal with most cancers and uncommon illnesses, for the first time in South Korea, it succeeded in creating a therapeutic antibody in 2006. ISU ABXIS has a pipeline of systematic analysis and administration for creating therapies for intractable illnesses from most cancers to uncommon illnesses, by means of that it has efficiently developed a new drug candidate for refractory most cancers and Hemophilia B, and many others. Its know-how advances in antibody-based platform for the remedy of human illness.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20221031005342/en/
